Log in

NASDAQ:MRNSMarinus Pharmaceuticals Stock Price, Forecast & News

$1.79
-0.02 (-1.10 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.74
Now: $1.79
$1.80
50-Day Range
$1.59
MA: $2.09
$2.73
52-Week Range
$1.01
Now: $1.79
$3.50
Volume975,952 shs
Average Volume1.26 million shs
Market Capitalization$218.73 million
P/E RatioN/A
Dividend YieldN/A
Beta2.04
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate exhibits anti-seizure, anti-depression, and anti-anxiety actions through its effects on synaptic and extrasynaptic GABAA receptors. It is also developing ganaxolone for cyclin-ependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, postpartum depression, refractory status epilepticus, and other indications. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Read More
Marinus Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRNS
CUSIPN/A
Phone484-801-4670

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.72 per share

Profitability

Net Income$-54,120,000.00

Miscellaneous

Employees28
Market Cap$218.73 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$1.79
-0.02 (-1.10 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRNS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions

How has Marinus Pharmaceuticals' stock price been impacted by COVID-19?

Marinus Pharmaceuticals' stock was trading at $1.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MRNS stock has increased by 9.1% and is now trading at $1.79.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Marinus Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Marinus Pharmaceuticals
.

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Marinus Pharmaceuticals
.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) announced its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.03.
View Marinus Pharmaceuticals' earnings history
.

What price target have analysts set for MRNS?

6 brokers have issued 12-month price objectives for Marinus Pharmaceuticals' shares. Their forecasts range from $4.50 to $9.00. On average, they anticipate Marinus Pharmaceuticals' share price to reach $6.00 in the next year. This suggests a possible upside of 235.2% from the stock's current price.
View analysts' price targets for Marinus Pharmaceuticals
.

Has Marinus Pharmaceuticals been receiving favorable news coverage?

News headlines about MRNS stock have trended negative recently, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Marinus Pharmaceuticals earned a coverage optimism score of -2.7 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Marinus Pharmaceuticals
.

Are investors shorting Marinus Pharmaceuticals?

Marinus Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 7,740,000 shares, an increase of 42.5% from the March 15th total of 5,432,400 shares. Based on an average daily volume of 1,130,000 shares, the short-interest ratio is currently 6.8 days.
View Marinus Pharmaceuticals' Short Interest
.

Who are some of Marinus Pharmaceuticals' key competitors?

What other stocks do shareholders of Marinus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tanker (NAT), The Gabelli Dividend & Income Trust (GDV), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Capricor Therapeutics (CAPR), Realty Income (O), Amarin (AMRN), Verastem (VSTM), Novavax (NVAX) and Geron (GERN).

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the following people:
  • Mr. Edward F. Smith, VP, CFO, Treasurer & Sec. (Age 48)
  • Mr. Christopher Michael Cashman, CEO, Pres & Director (Age 62)
  • Dr. Lorianne K. Masuoka, Chief Medical Officer (Age 58)
  • Dr. Scott Braunstein, Exec. Chairman (Age 56)
  • Ms. Lisa M. Caperelli, Exec. Director of Investor & Strategic Relations

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alyeska Investment Group L.P. (2.30%), Granite Point Capital Management L.P. (1.84%), Jefferies Group LLC (1.66%), FMR LLC (1.09%), WINTON GROUP Ltd (0.98%) and Monashee Investment Management LLC (0.66%). Company insiders that own Marinus Pharmaceuticals stock include Christopher Michael Cashman, Edward F Smith and Scott Braunstein.
View institutional ownership trends for Marinus Pharmaceuticals
.

Which major investors are selling Marinus Pharmaceuticals stock?

MRNS stock was sold by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., WINTON GROUP Ltd, and UBS Group AG.
View insider buying and selling activity for Marinus Pharmaceuticals
.

Which major investors are buying Marinus Pharmaceuticals stock?

MRNS stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Monashee Investment Management LLC, Alyeska Investment Group L.P., Granite Point Capital Management L.P., Goldman Sachs Group Inc., California Public Employees Retirement System, Virtus ETF Advisers LLC, and Jefferies Group LLC.
View insider buying and selling activity for Marinus Pharmaceuticals
.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $1.79.

How big of a company is Marinus Pharmaceuticals?

Marinus Pharmaceuticals has a market capitalization of $218.73 million. The biopharmaceutical company earns $-54,120,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Marinus Pharmaceuticals employs 28 workers across the globe.

What is Marinus Pharmaceuticals' official website?

The official website for Marinus Pharmaceuticals is www.marinuspharma.com.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.